Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Strategy Generic Drugs United States

Sandoz Seeks Help From Doctors For US Symjepi Push

  • News

Executive Summary

Sandoz is encouraging US doctors to write prescriptions for epinephrine that include its Symjepi pre-filled syringes, and not just for auto-injector devices, as it targets the retail sector.

You may also be interested in...



Sandoz Phases US Epinephrine Entry

Sandoz will first focus on the US institutional channel on which it is increasingly concentrating its attention as it rolls out its alternative to Mylan’s EpiPen epinephrine auto-injector.

Sandoz’ Symjepi Set To Undercut Rivals

Sandoz has set a US launch price for its Symjepi epinephrine anaphylaxis treatment that is significantly below that of Mylan’s EpiPen and Teva’s generic.

Pressure Mounts For German Tender Reforms

Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.

Table

View full table

Topics

Related Companies

Tags:
Strategy Generic Drugs United States
Latest Headlines

Sandoz Prepares For European Natalizumab Launch As Approval Arrives

US FDA's Cavazzoni Criticizes Plant Shutdown That Triggered Serious Cisplatin Shortage

‘There Is Always Room For Improvement’: Celltrion Reflects On A Decade Of European Biosimilars

Fresenius Kabi Gets Ready To Launch Europe’s First Tocilizumab Rival

See All
UsernamePublicRestriction

Register

GB140491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By